Caris Life Sciences (CAI) Payables (2024 - 2026)

Caris Life Sciences (CAI) posted quarterly Payables of $69.8 million for Q1 2026, up 78.04% quarter-over-quarter from $39.2 million in Q4 2025.

Caris Life Sciences (CAI) Payables (2024 - 2026) Analysis & Trends

Caris Life Sciences' Payables history runs 3 years deep, the most recent figure standing at $69.8 million for Q1 2026.

In Q1 2026, Payables changed N/A year-over-year to $69.8 million; the TTM figure through Mar 2026 stood at $69.8 million (changed N/A YoY), while the FY2025 annual figure was $39.2 million, up 41.07% from the prior year.
Payables for Q1 2026 stood at $69.8 million, up from $39.2 million in the prior quarter.
The five-year high for Payables was $69.8 million in Q1 2026, with the low at $27.8 million in Q4 2024.
The 3-year median for Payables is $29.0 million (2025), against an average of $38.9 million.
Peak annual rise in Payables reached 41.07% in 2025, while the deepest fall reached 41.07% in 2025.
Caris Life Sciences' Payables stood at $27.8 million in 2024, then jumped by 41.07% to $39.2 million in 2025, then jumped by 78.04% to $69.8 million in 2026.
Business Quant data shows CAI's Payables at $69.8 million in Q1 2026, $39.2 million in Q4 2025, and $29.0 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Payables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	429.50 Mn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.16 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.52 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	88.42 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	470.30 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3.05 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	35.57 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	108.02 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	428.93 Mn
10	Caris Life Sciences	6.16 Bn	5.37 Bn	182.38 Mn	85.99 Mn

Download Data